BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9411 related articles for article (PubMed ID: 14666719)

  • 1. The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts.
    Tejeda M; Gaal D; Barna K; Csuka O; Kéri G
    Anticancer Res; 2003; 23(5A):4061-6. PubMed ID: 14666719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of the somatostatin structural derivative (TT-232), against mouse and human melanoma tumor models.
    Tejeda M; Gaál D; Hullán L; Schwab R; Szokoloczi O; Kéri G
    Anticancer Res; 2007; 27(6B):4015-9. PubMed ID: 18225564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models.
    Tejeda M; Gaál D; Hullán L; Csuka O; Schwab R; Szokoloczi O; Kéri G
    Anticancer Res; 2006; 26(4B):3011-5. PubMed ID: 16886628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models.
    Tejeda M; Gaál D; Hullán L; Hegymegi-Barakonyi B; Kéri G
    Anticancer Res; 2006; 26(5A):3477-83. PubMed ID: 17094470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous administration of the somatostatin structural derivative /TT-232/ by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models.
    Tejeda M; Gaal D; Hullán L; Csuka O; Schwab R; Szokoloczi O; Kéri GY
    Anticancer Res; 2008; 28(5A):2769-74. PubMed ID: 19035308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity.
    Teplán I
    Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models.
    Tejeda M; Gaál D; Csuka O; Kéri G
    Anticancer Res; 2005; 25(1A):325-30. PubMed ID: 15816555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of various administration routes on the antitumor efficacy ofTT-232, a novel somatostatin analog.
    Tejeda M; Gaal D; Schwab RE; Pap A; Szúts T; Keri G
    Anticancer Res; 2000; 20(2A):1023-7. PubMed ID: 10810391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and tumours.
    Schwab RE; Froidevaux S; Paku S; Tejeda M; Szende B; Pap A; Beglinger C; Eberle AN; Kéri G
    Anticancer Res; 2001; 21(1A):71-5. PubMed ID: 11299792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo antitumor activity of TT-232 a novel somatostatin analog.
    Tejeda M; Gaal D; Schwab RE; Pap A; Keri G
    Anticancer Res; 1999; 19(4B):3265-8. PubMed ID: 10652622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
    Bernacki RJ; Oberman EJ; Seweryniak KE; Atwood A; Bergeron RJ; Porter CW
    Clin Cancer Res; 1995 Aug; 1(8):847-57. PubMed ID: 9816054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
    Shindoh N; Mori M; Terada Y; Oda K; Amino N; Kita A; Taniguchi M; Sohda KY; Nagai K; Sowa Y; Masuoka Y; Orita M; Sasamata M; Matsushime H; Furuichi K; Sakai T
    Int J Oncol; 2008 Mar; 32(3):545-55. PubMed ID: 18292931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
    Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
    Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.
    Drees M; Dengler WA; Roth T; Labonte H; Mayo J; Malspeis L; Grever M; Sausville EA; Fiebig HH
    Clin Cancer Res; 1997 Feb; 3(2):273-9. PubMed ID: 9815683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
    Al-Saffar NM; Troy H; Ramírez de Molina A; Jackson LE; Madhu B; Griffiths JR; Leach MO; Workman P; Lacal JC; Judson IR; Chung YL
    Cancer Res; 2006 Jan; 66(1):427-34. PubMed ID: 16397258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationship studies of novel somatostatin analogs with antitumor activity.
    Kéri G; Mezô I; Vadász Z; Horváth A; Idei M; Vántus T; Balogh A; Bökönyi G; Bajor T; Teplán I
    Pept Res; 1993; 6(5):281-8. PubMed ID: 7903057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 471.